On the other hand, blocking C5 activation prevents the proinflammatory and prothrombotic actions of the terminal products of the C cascade (C5a and C5b-9) activated by SARS-CoV-2, whilst preserving the activity of early C components involved in viral clearance and activation of the adaptive immune response (218); although, this exposes patients to the risk of developing other infections, especially bacterial (219). Here, C5 is linked to infection.